CTNM — Contineum Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $106.07m
- -$98.69m
Annual balance sheet for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 69 | 47.2 | 125 | 205 |
| Prepaid Expenses | ||||
| Total Current Assets | 69.8 | 48.4 | 128 | 206 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.642 | 2.12 | 1.4 | 6.46 |
| Other Long Term Assets | ||||
| Total Assets | 70.5 | 50.6 | 130 | 213 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Current Liabilities | 3.67 | 7.55 | 5.48 | 9.97 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 8.93 | 11.4 | 5.7 | 14.8 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 61.6 | 39.3 | 125 | 198 |
| Total Liabilities & Shareholders' Equity | 70.5 | 50.6 | 130 | 213 |
| Total Common Shares Outstanding |